Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study

Documents similaires

• A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
  par: Richard B. Lipton, et autres
  Publié: (2024)
• Developing and delivering a migraine disparities and diagnosis undergraduate medical educational program to underrepresented in medicine medical student members of the Student National Medical Association: A pilot project
  par: Larry Charleston
  Publié: (2024)
• Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
  par: Larry Charleston, et autres
  Publié: (2026)
• The impact of headache intensity on speech in participants with migraine and acute post‐traumatic headache
  par: Dani C. Smith, et autres
  Publié: (2024)
• A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
  par: David Kudrow, et autres
  Publié: (2025)